{"id":"NCT04109391","sponsor":"Tanvex BioPharma USA, Inc.","briefTitle":"Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03","officialTitle":"A Double-blinded Extension Study to Provide Adjuvant Treatment With Single Agent HerceptinÂ® or TX05 and Assess Continued Safety and Immunogenicity in Subjects With HER2-positive Early Breast Cancer Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-08-20","primaryCompletion":"2021-12-25","completion":"2022-03-08","firstPosted":"2019-09-30","resultsPosted":"2022-10-26","lastUpdate":"2022-10-26"},"enrollment":338,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["HER2-positive Breast Cancer","Early-stage Breast Cancer","Breast Cancer","Breast Neoplasms","Stage II Breast Cancer","Stage IIIA Breast Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"TX05 (trastuzumab)","otherNames":[]},{"type":"BIOLOGICAL","name":"Herceptin (trastuzumab)","otherNames":[]}],"arms":[{"label":"Test Product (TX05)","type":"EXPERIMENTAL"},{"label":"Reference Therapy (Herceptin)","type":"ACTIVE_COMPARATOR"},{"label":"Test Product (Herceptin/TX05 Transition)","type":"EXPERIMENTAL"}],"summary":"This is an extension study to provide adjuvant treatment with single agent Herceptin or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03.","primaryOutcome":{"measure":"Immunogenicity Assessments (ADA and Nab)","timeFrame":"Assessed from first infusion through end of treatment (Week 45) or Early Termination visit. Each cycle is 3 weeks.","effectByArm":[{"arm":"Test Product (TX05 Only)","deltaMin":3,"sd":null},{"arm":"Reference Therapy (Herceptin Only)","deltaMin":2,"sd":null},{"arm":"Test Product (Herceptin/TX05 Transition)","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":86,"countries":["Belarus","Chile","Georgia","Hungary","India","Mexico","Peru","Philippines","Russia","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":175},"commonTop":["Radiation Skin Injury","Headache","Asthenia","Arthralgia","Respiratory Tract Infection"]}}